Behavioral Science in Clinical Trials: Unleashing the Benefits and Eliminating Bias

This webinar will explore the benefits of incorporating behavioral science into clinical trials. The featured speakers will focus on how this approach can lead to improved trial design, increased patient engagement and reduced bias in data collection and analysis.

By utilizing behavioral science principles, clinical trial teams can better understand and address the factors that influence patient behavior and decision-making. This results in more accurate data collection and a more representative sample, leading to a greater understanding of the true efficacy and safety of treatments being tested.

Additionally, the application of behavioral science in clinical trials can improve patient engagement and retention, leading to a more successful trial outcome.

Finally, the webinar will discuss the importance of reducing bias in clinical trials and how behavioral science can help achieve this goal. From improved study design to reducing bias in data collection, this approach has the potential to revolutionize the clinical trial process and bring clinical trials closer to discovering life-saving treatments for patients in need.

Join the speakers to learn more about the benefits of behavioral science in clinical trials and how attendees can use this approach to make a difference in their own research.

Attendees will walk away with the following key takeaways:

• What behavioral science is and its importance in the clinical trials industry
• Strategies for improving patient engagement, retention and compliance in clinical trials
• The importance of reducing bias in clinical trials and how behavioral science can achieve this goal

Speakers

Marie Onakomaiya, Chief Scientific Officer, Datacubed Health

Behavioral neuroscientist, clinical epidemiologist and policy analyst, Dr. Marie Onakomaiya has spent her career working on complex issues in mental health, neurological and chronic conditions and digital health research. Recognized for her commitment to patient-centricity, Dr. Onakomaiya is a champion for adopting a new model of eCOA that has behavioral science at its core. Dr. Onakomaiya received her PhD in experimental and molecular medicine (neurosciences) from Dartmouth College. She also holds an MPH from Columbia University’s Mailman School of Public Health and a BSc in biochemistry from Babcock University.

Message Presenter

Kyle Hogan, President, Datacubed Health

Kyle Hogan has been dedicated to advancing the voice of the patient through the promise of ePRO/eCOA since 2007, in that time, helping deliver hundreds of successful trials for CROs and pharmaceutical companies globally. He is a recognized expert in implementing innovative and patient-centric ePRO/eCOA solutions with an aim to achieve sponsor confidence and study success across all phases of clinical trials.

Message Presenter